NIDA Program Project Grant Applications (P01 Clinical Trial Optional)
ID: 345314Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/345314

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-23-064.html
Timeline
    Description

    The National Institutes of Health (NIH) is inviting applications for the NIDA Program Project Grant (P01 Clinical Trial Optional), aimed at supporting collaborative, multidisciplinary research addressing critical issues related to substance use and its consequences. This funding opportunity requires applicants to propose a minimum of three interrelated research projects that demonstrate scientific merit and thematic cohesion, supported by an administrative core, to foster synergistic outcomes that enhance the overall program's impact. This initiative reflects NIH's commitment to advancing addiction research through collaboration across various fields, including neuroscience, genetics, and health services. Interested applicants, including higher education institutions and nonprofit organizations, must submit their proposals by January 7, 2026, and can find additional information and application guidelines at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-23-064-Full-Announcement.html
    PAR-23-064.html
    The National Institute on Drug Abuse (NIDA) is inviting grant applications for Program Project Grants (P01) with an optional clinical trial component, focusing on multidisciplinary research addressing critical issues related to substance use and its consequences. This opportunity aims to gather collaborative teams to explore areas such as neuroscience, genetics, HIV/AIDS, and health services that affect individuals with substance use disorders. Applications must include at least three interrelated research projects demonstrating scientific merit and similar thematic goals, supported by an administrative core. The application timeline indicates several submission deadlines in 2023 and 2024, with a maximum project duration of up to five years and no budget limits specified. A critical component of the application is the Plan for Enhancing Diverse Perspectives (PEDP) to promote inclusivity and address disparities in the research context. Eligible applicants include various entities, such as higher education institutions and nonprofit organizations. The document outlines comprehensive instructions on applications, evaluations, eligibility, and submission processes, emphasizing adherence to NIH guidelines throughout. This funding opportunity reflects NIH's commitment to advancing addiction research by fostering collaboration and innovation across multiple disciplines.
    Similar Opportunities
    NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) to enhance research on substance use, addiction, and HIV through collaborative efforts among investigators. This program aims to integrate diverse new and early career researchers, particularly from underrepresented backgrounds, to develop innovative approaches and interdisciplinary projects that transform the scientific research landscape. Eligible applicants include higher education institutions, nonprofits, for-profit organizations, and government entities, with a maximum project period of five years and a requirement to submit a Plan for Enhancing Diverse Perspectives (PEDP) as part of the application. Interested parties should note that the application deadline is November 17, 2025, and can find more information at NIH Grants or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering the P50 Research Center of Excellence Grant Program to support innovative research in substance use and addiction. This program aims to establish multidisciplinary research centers that not only advance scientific knowledge but also serve as national resources for education and outreach within the drug abuse research community. The initiative encourages applications that focus on integrated themes rather than incremental work, with a budget limit of $10 million over five years and a maximum of 25% of direct costs allocated to pilot projects. Interested applicants should note that the submission process requires adherence to specific guidelines, including a Plan for Enhancing Diverse Perspectives (PEDP), and key deadlines extend until November 18, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Program Project Grant (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Neurological Disorders and Stroke (NINDS), is offering the Program Project Grant (P01) to support innovative, collaborative research addressing significant scientific questions within its mission. This grant encourages multi-disciplinary projects that are interdependent, allowing for greater scientific advancements than individual efforts, and applications may include clinical trials, although those focused on intervention effectiveness should seek different funding opportunities. Eligible applicants include higher education institutions, nonprofits, and governmental entities, with funding of up to $1 million in direct costs per year available for a maximum project period of five years. Interested parties should consult with NINDS staff early in the proposal process, with the application submission period opening on April 25, 2024, and due by May 25, 2024; for further inquiries, contact grantsinfo@nih.gov.
    NIA Program Project Applications (P01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the NIA Program Project Grants (P01 Clinical Trial Optional), aimed at advancing research in aging-related scientific areas. Applicants must propose at least three interrelated research projects centered around a common theme, along with an administrative core to manage the initiative, addressing topics such as genetics, biology, and Alzheimer’s disease. This funding opportunity is crucial for fostering collaborative research efforts among established scientists and early-career researchers, ultimately contributing to the understanding and improvement of public health concerning aging. Interested organizations must submit their applications by September 7, 2025, and can find additional details and requirements at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.
    Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), is offering a funding opportunity titled "Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional)" aimed at accelerating the development of medications for Substance Use Disorders (SUDs). This initiative encourages research applications for diverse preclinical and clinical projects that can expedite the FDA approval process for new treatments, addressing the significant public health need for effective therapies for conditions such as cocaine, methamphetamine, and cannabis use disorders. The program will provide cooperative agreements for projects lasting up to three years, with annual budgets capped at $5 million, and applications are accepted on a rolling basis with specific due dates for scientific merit review established throughout 2023 and 2024. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-22-202.html.
    NIDA Animal Genomics Program (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIDA Animal Genomics Program (U01), aimed at exploring the genetic and molecular factors associated with substance use disorders (SUD). This cooperative agreement encourages research that identifies genetic, genomic, and epigenetic variants influencing addictive behaviors and related comorbidities, utilizing diverse methodologies such as multi-omics and artificial intelligence. The program is open to a wide range of eligible applicants, including higher education institutions and nonprofit organizations, with no budget cap for proposals, although budgets should reflect actual project needs. Applications are due by February 12, 2027, with an opening date for submissions on January 11, 2025. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "High Priority HIV and Substance Use Research (RM1 Clinical Trial Optional)" aimed at supporting innovative research that addresses the intersection of HIV and substance use. This initiative invites applications from individual researchers and research teams to develop projects that can lead to new prevention, treatment, and care strategies for individuals affected by both conditions, with a requirement for a detailed research plan and preliminary data. A total budget of $3.0 million is available for funding one to two awards, with individual project budgets capped at $1.5 million per fiscal year, and applications are due by February 12, 2027. Interested applicants can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries and are encouraged to consult with NIDA program staff early in the application process.
    NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Research Education Program for Clinical Researchers and Clinicians under Funding Opportunity Number PAR-25-204, aimed at enhancing the training of clinicians and clinical researchers in substance use disorder (SUD) research. This program seeks to address the shortage of qualified professionals in the field by supporting educational activities that develop skills and provide hands-on research experiences, particularly targeting underrepresented groups in the workforce. With a budget of up to $350,000 annually for a project duration not exceeding five years, the program is open for applications starting February 11, 2025. Interested applicants can find more information and guidelines at the NIH Grants website or contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Exploratory Clinical Neuroscience Research on Substance Use Disorders" (R61/R33), aimed at supporting innovative clinical research that explores the neurobiological mechanisms underlying substance use disorders (SUD). This initiative encourages applications that investigate neural circuitry and cognitive processes affecting substance use behavior, particularly in the context of the ongoing public health crisis related to SUDs, including the opioid epidemic. The R61/R33 mechanism allows for up to five years of funding, divided into an initial two-year R61 phase and a potential three-year R33 phase, contingent upon meeting specified milestones. Interested applicants can find more information and submit proposals by the application due date of March 13, 2026, and may contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NIDA Avant-Garde Program for HIV and Substance Use Disorder Research (DP1 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering the NIDA Avant-Garde Program for HIV and Substance Use Disorder Research, aimed at supporting innovative research that intersects HIV and substance use disorders. This grant opportunity encourages creative scientists to propose high-impact studies that lead to new therapies and preventative strategies for HIV among drug users, emphasizing originality and alignment with NIH’s HIV/AIDS research priorities. The program allows for clinical trial proposals with a funding ceiling of $700,000 per year for up to five years, with applications due by August 15, 2025. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.